NEDD4L and plasma cell myeloma: Our finding that low expression of NEDD4L attenuated the anti-MM activity of Bor both in vitro and in vivo provides a biological rationale for the use of a NEDD4L activator in combination with Bor as a novel therapeutic strategy for the treatment of multiple myeloma.